Biotage AB a global leader in tools and technology for medicinal and analytical chemistry, and the owners of MIP Technologies AB today announced that the parties have signed a definitive agreement under which Biotage will acquire all outstanding shares in MIP Technologies, a privately held leading developer of molecularly imprinted polymers (MIPs) and other novel polymers.

MIP Technologies, located in Lund, Sweden is a company working at the boundary of chemistry and materials science. Founded in 2000, the company has developed ground breaking solutions for the separations field using proprietary Molecularly Imprinted Polymer (MIP) technology and other novel polymer chemistries. The company is currently providing state-of-the-art solutions for several multi-national blue chip customers in the food and beverage industries and develops front line analytical products for food, environmental, veterinary and pharmaceutical laboratories, including many of the top government central laboratories monitoring chemicals in food and health products

This is an excellent strategic fit regarding Biotages expansion and diversification into markets outside of pharma and it will certainly fuel our efforts within Sample Prep. One of our ambitions going forward is to further develop our Sample Prep business and to drive our consumables sales to get a more even balance between the sale of instruments and consumables. says Torben Jörgensen, Biotage AB President and CEO The addition of MIP Technologies continues the advancement of our vision of complete solutions for the scientific community. We are very excited about the technology that will benefit our customers and fit perfectly with our product offering. MIP Technologies will bring outstanding competencies which strengthen our own and we have the experience, knowledge and resources they need to reach the global market.

We are all very excited about joining the Biotage organization. says Anthony Rees, MIP Technologies CEO. Our MIP and non MIP polymer technologies compliment Biotages product offering and Im especially thrilled that the direct and indirect sales, distribution and service from Biotage are world-class. says Rees The combined capabilities within existing R & D organizations and production units will allow us to further profit on the current businesses but also to venture into new areas.

Redsense Medical AB has secured venture capital from Teknoseed and Almi Invest to market its product offering globally. Redsense Medical has developed an alarm device designed to detect venous needle dislodgement during hemodialysis. Over 200,000 incidents related to this procedure occur annually, several hundred of them with a lethal outcome.

Redsense Medical has solved a problem known for many years in the field of dialysis treatment by launching an alarm device that efficiently detects whether the venous needle in the patient’s arm becomes loose and is subsequently dislodged during hemodialysis. Existing alarm solutions have major defects, and the alert eyes of the care staff have hitherto been the only thing to reliably stop the dialysis machine from continuing to pump out the patient’s blood if the needle became dislodged. In the event of it becoming loose, it is only a matter of a few minutes before the patient risks serious harm. If the bleeding is detected in time, the patient may need medical treatment, possibly even intensive care, whereas undetected bleeding leads to death. Several hundred deaths occur annually around the world.

A total of 1.9 million patients undergo more than 250 million dialysis treatments annually. The market is growing continuously as people live longer, as more and more are affected by type-II diabetes and as the survival rate for serious kidney problems increases. In addition, self-treatment via home dialysis is becoming increasingly common in certain parts of the world, thus increasing the need for reliable alarm systems. Redsense Medical is responding to this need, which has been identified on the market for many years, and the company has now started setting up sales outlets in some ten countries, using the investments principally for continued market development.

”The dialysis industry has long sought an effective method of detecting blood loss during venous needle dislodgement, and Redsense has now given us access to a disposable-based sound sensor that saves lives”, says Marcus Skärbäck, a Partner at Teknoseed Portfolio Management.

”We are pleased to support Redsense in their work in making dialysis safer and look forward to working with a team with extensive experience in both product development and international sales” says Håkan Krook, CEO of Almi Invest in western Sweden.

”Almi has supported the company from the beginning, first with seed capital and now as an investor” – says Patrik Byhmer, CEO of Redsense Medical. ”Teknoseed and Almi Invest have the know-how, networks and capital to support the company’s development and we appreciate acquiring these investors as active joint owners. The new share issue gives us the preconditions to develop the company and further strengthen our marketing efforts”, he adds.

LocalizeDirect has secured funding from TeknoSeed, the leading venture capital firm in southern Sweden, in order to finalize and launch a system for efficient localization of video games including digital games, a sector showing explosive growth.

With a real time based localization process, new games are launched faster and to a broader market. TeknoSeed will invest an initial Euro 250.000 which will secure market introduction in 2010.
 
The system, called LocalizeDirect, is an online solution enabling real time localization of text strings, directly connecting all the stakeholders in the process; including developers, producers, translators, proofreaders, localization managers and QA staff.

- We are pleased to become investors in a very interesting venture with the potential to reshape the expanding market for software localization. The founders of the company are serial entrepreneurs with vast experience from the gaming industry and development of advanced internet based transaction systems, giving us solid ground upon which to build a successful company, said Marcus Skärbäck, Partner at TeknoSeed.

- We are very pleased to gain TeknoSeed as investor and partner in LocalizeDirect, as we are now launching our localization solution, says Christoffer Nilsson, Managing Director at LocalizeDirect AB.
- Localizing video games into different geographical regions is a must. This has become an extremely important factor in increasing sales. Publishers and developers are targeting more languages than ever before, game development complexity has continued to increase but the localization process has stayed the same. Traditionally, localizing gaming products has been complex and slow, causing delayed market introduction and reduced profits. With LocalizeDirect, developers and publishers can improve their localization process, save valuable time and increase the quality of localized versions, continues Christoffer Nilsson.

Scalado meddelar idag att vid bolagsstämman i juni valdes Anders Lidbeck och Mats Lindoff in som nya ledamöter i styrelsen. "Scalado är ett mycket unikt företaget som jag följt lite på avstånd under flera år. Jag ser verkligen fram emot att nu få engagera mig i bolaget via styrelsen", säger Anders Lidbeck. Anders var under många år VD för Telelogic och har lång erfarenhet av IT och mjukvaruindustrin.

Mats Lindoff har lång erfarenhet av telekomindustrin och lämnade under våren tjänsten som Chief Technology Officer vid Sony Ericsson Mobile Communications."Jag har stor respekt för Scalados teknik och produkter som är världsledande på flera områden. Det skall bli väldigt spännande att få vara med i styrelsen", säger Mats Lindoff.

Vid bolagsstämman avtackades dessutom ordförande Anders Cedervall och den nya styrelsen valde Per Aspemar till ny ordförande. Per har varit medlem i styrelsen sedan juni 2008 och arbetar idag vid riskkapitalbolaget TeknoSeed Portfolio Management. Tidigare hade Per olika chefsroller inom Sony Ericsson Mobile Communications bla Head of Corporate Strategy. "Det känns väldigt bra att få in Anders och Mats i styrelsen. Tillsammans för de med sig oerhört mycket kunnande inom många olika områden. För Scalado som fortsätter att expandera och satsar internationellt innebär den nya styrelsesammansättningen ett stort lyft för bolaget", säger Per Aspemar.

Innovationsbron has decided to shift its focus away from the Seed stage and the Startup stage towards the Pre-seed stage. As a consequence, Innovationsbron has reduced its ownership from 100% to 30% in the management of the funds TeknoSeed I and TeknoSeed II.

Per Heander, previously at TeknoSeed, has taken up a new position as Investment Manager, Pre-Seed at Innovationsbron.

Per Aspemar and Marcus Skärbäck, previously at TeknoSeed, have joined Mats Johansson as Partners at TeknoSeed Portfolio Management, the new management company advising funds TeknoSeed I and TeknoSeed II. TeknoSeed Portfolio Management is owned 70% by the Partners and 30% by Innovationsbron.

Innovationsbron is the only Limited Partner in TeknoSeed I. The Limited Partners in TeknoSeed II are Innovationsbron (48%), IKANO, Länsförsäkringar Skåne, Sparbanken Finn, Ideonfonden and TeknoSeed Portfolio Management AB.